Johnson & Johnson has received a consensus rating of Hold. The company's average rating score is , and is based on 6 buy ratings, 7 hold ratings. JNJ is and has been a safety stock for a long time. This is a great dip to buy IMO. It doesn't need to triple to offer a good risk/reward but. Go to inter-sites.ru NYSE: JNJLast updated: 8/26/ PM. + (%)See all stock information. showing slide 1 of 1. Johnson & Johnson Second Quarter. The intrinsic value of one JNJ stock under the Base Case scenario is USD. Compared to the current market price of USD, Johnson & Johnson is. The stock looks undervalued, with the market likely not fully appreciating the broad innovation across the firm's pipeline that should drive steady growth and.
JNJ is good value based subscribe to Premium to read more. P/E vs If you're new to stock investing, here's how to buy Johnson & Johnson stock. Johnson & Johnson Stock Falls After Earnings Beat. Talc Issues Loom. April 5, a.m. ET. Johnson & Johnson to Buy Shockwave Medical for $ Billion. Overall, Johnson & Johnson stock has a Value Grade of D, Growth Grade of B, Quality Grade of A, Momentum Grade of C. Whether or not you should buy Johnson &. Go to inter-sites.ru NYSE: JNJLast updated: 8/26/ PM. + (%)See all stock information. showing slide 1 of 1. Johnson & Johnson Second Quarter. Stock Price Targets. High, $ Median, $ Low, $ Average, $ Current Price, $ Yearly Numbers. Estimates. JNJ will report Analyst Ratings Johnson & Johnson ; Overweight. 3. 3 ; Hold. 12 ; Underweight. 0. 0 ; Sell. 0. 0. 7 of the Best Fidelity Bond Funds to Buy · Stocks Buffett Just Bought and Sold Advice, rankings and one great story every day. Sign Up. Sign up to receive. Stock Price Target ; High, $ ; Low, $ ; Average, $ ; Current Price, $ Is Johnson & Johnson Stock Undervalued? The current Johnson & Johnson [JNJ] share price is $ The Score for JNJ is 39, which is 22% below its historic. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical. Johnson & Johnson is regaining momentum with strong growth in its Innovative Medicine and MedTech segments, driven by new products and strategic acquisitions.
JNJ (JNJ) reported Q2 earnings per share (EPS) of $, beating estimates of $ by %. In the same quarter last year, JNJ's earnings per share (EPS). We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months. We have upgraded our analysis. Johnson & Johnson stock outperforms competitors on strong trading day. Aug Is Johnson & Johnson Stock a Buy? Aug. 25, at a.m. ET on Motley. Lightning Round: Elf is without a doubt one of the most shorted stocks on the market, says Jim Cramer · Cramer's Lightning Round: Dell is a buy 1 Hour Ago CNBC. Out of 8 analysts, 3 (%) are recommending JNJ as a Strong Buy, 1 (%) are recommending JNJ as a Buy, 4 (50%) are recommending JNJ as a Hold, 0 (0%) are. Johnson & Johnson has a consensus price target of $ based on the ratings of 21 analysts. The high is $ issued by Cantor Fitzgerald on August 5, Research Analysis: JNJ. View More. Earnings Per Share. Consensus EPS. Analyst Recommendations. Strong Buy. Buy. Hold. Underperform. Sell. Analyst Price Targets. Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 49 buy ratings, 32 hold ratings, and 1 sell. Johnson & Johnson (JNJ) has a Smart Score of 10 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund.
JNJ Stock Overview · Trading at 39% below our estimate of its fair value · Earnings are forecast to grow % per year · Earnings grew by % over the past year. Is Johnson & Johnson stock A Buy? Johnson & Johnson holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend. Johnson & Johnson's stock price has surged recently. Jim Cramer advises investors to wait for a pullback before buying, as the stock is currently viewed as. Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. It has underperformed other stocks in the Drug Manufacturers - General industry by percentage points. Johnson & Johnson stock is currently +% from its.
(Live) Pre-Market-Prep - NVDA Earnings! - SPY/QQQ/NVDA - Wednesday
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 7 hold ratings and 6 buy. What is the forecast, or price target, for Johnson & Johnson (JNJ) stock? A. Johnson & Johnson has a consensus price target of $ Q. What is.